Showing results (551-560 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|September 8, 2024
Optimising HIV spending in 12 eastern European and central Asian countries: a modelling studyDebra C Ten Brink, Anna L Bowring, Rowan Martin-Hughes, et al.
The Lancet. HIV|September 16, 2024
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort studySam Nightingale, Anna J Dreyer, Kevin G F Thomas, et al.
The Lancet. HIV|May 15, 2026
Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trialRoland Landman, Lambert Assoumou, Sidonie Lambert-Niclot, et al.
The Lancet. HIV|May 1, 2026
Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trialEsteban Martínez, Maya Watanabe, Risa Hoffman, et al.
The Lancet. HIV|July 15, 2023
Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysisJames Stannah, Nirali Soni, Jin Keng Stephen Lam, et al.
The Lancet. HIV|August 4, 2023
Is the USA on track to end the HIV epidemic?Vincent Guilamo-Ramos, Marco Thimm-Kaiser, Adam Benzekri
The Lancet. HIV|August 4, 2023
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation studyKristina M Brooks, Jennifer J Kiser, Lauren Ziemba, et al.
The Lancet. HIV|June 10, 2023
Ending AIDS deaths requires improvements in clinical care for people with advanced HIV disease who are seriously illRachael M Burke, Nicholas Feasey, Ajay Rangaraj, et al.
The Lancet. HIV|June 11, 2023
HIV infection and engagement in the care continuum among migrants and refugees from Venezuela in Colombia: a cross-sectional, biobehavioural surveyAndrea L Wirtz, José Rafael Guillén, Megan Stevenson, et al.
The Lancet. HIV|May 9, 2026
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trialEric G Meissner, Moti Ramgopal, Peter J Ruane, et al.
Pageof 79